Biotech · Private company
Polaris Group
Track this companyFree. Adds Polaris Group to your Dealase workspace and tells you when its record changes.
Clinical trials122 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- ADI PEG20Phase 3 · Soft Tissue SarcomaClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)Phase 3 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20 plus Pem PlatinumPhase 3 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- Best Supportive CarePhase 3 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20 plus modified FOLFOX6Phase 2 · Advanced Gastrointestinal (GI) MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20Phase 1 · Acute Myeloid Leukemia, AdultClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20Phase 1 · Advanced Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- ADI-PEG 20Phase 1 · Pleural Mesothelioma Malignant AdvancedClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue SarcomaPHASE1 · TERMINATED · started Mar 14, 2024ClinicalTrials.gov NCT05813327 · fetched Nov 12, 2026
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)PHASE3 · TERMINATED · started Nov 29, 2023ClinicalTrials.gov NCT05712694 · fetched Nov 12, 2026
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersPHASE1_PHASE2 · TERMINATED · started Apr 5, 2023ClinicalTrials.gov NCT05616624 · fetched Nov 12, 2026
- Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 5, 2022ClinicalTrials.gov NCT05001828 · fetched Nov 12, 2026
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPHASE2_PHASE3 · RECRUITING · started Jul 30, 2019ClinicalTrials.gov NCT03970447 · fetched Nov 12, 2026
- Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and CisplatinPHASE2_PHASE3 · COMPLETED · started Aug 1, 2017ClinicalTrials.gov NCT02709512 · fetched Nov 12, 2026
- PH 2 ADI-PEG 20 Acute Myeloid LeukemiaPHASE2 · COMPLETED · started Jan 6, 2015ClinicalTrials.gov NCT01910012 · fetched Nov 12, 2026
- Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic CancerPHASE1 · COMPLETED · started Nov 17, 2014ClinicalTrials.gov NCT02101580 · fetched Nov 12, 2026
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular CarcinomaPHASE1_PHASE2 · TERMINATED · started Nov 1, 2014ClinicalTrials.gov NCT02102022 · fetched Nov 12, 2026
- Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and CisplatinPHASE1 · TERMINATED · started Apr 23, 2014ClinicalTrials.gov NCT02029690 · fetched Nov 12, 2026
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic TherapyPHASE3 · COMPLETED · started Jul 1, 2011ClinicalTrials.gov NCT01287585 · fetched Nov 12, 2026
- Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung CancerPHASE2 · TERMINATED · started Jan 1, 2011ClinicalTrials.gov NCT01266018 · fetched Nov 12, 2026